-
Sunshine Lake Pharma Inks Licensing Deal with Apollo Therapeutics for APL-18881
•
China-based Sunshine Lake Pharma Co., Ltd., (HKG: 1558) a member of the HEC Group, has entered into a licensing agreement with UK-headquartered Apollo Therapeutics Group Limited for the development of APL-18881 (HEC88473). This strategic deal grants Apollo exclusive rights to develop and commercialize the drug outside of Greater China, while…
-
Sihuan Pharmaceutical Plans IPO for Xuanzhu Biopharm on Hong Kong Stock Exchange
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced a renewed attempt to spin off its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd (Xuanzhu Biopharm), for an initial public offering (IPO) on the Hong Kong Stock Exchange. This follows an earlier aborted effort to list on Shanghai’s Sci-Tech Innovation Board (STAR)…
-
Boehringer Ingelheim Joins MTM Vision Consortium to Advance Diabetes Retinopathy Research
•
Germany-based pharmaceutical major Boehringer Ingelheim has announced the initiation of a long-term collaboration with the Mary Tyler Moore Vision Initiative (MTM Vision), marking the first time a pharmaceutical company has joined the MTM Vision Consortium. This partnership signifies a significant step in collaborative research aimed at addressing vision-related complications of…
-
J&J MedTech Receives FDA IDE for OTTAVA Robotic Surgical System Trials
•
US-based Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received an investigational device exemption (IDE) from the US Food and Drug Administration (FDA), allowing its OTTAVA robotic surgical system to commence clinical trials at various sites across the United States. This approval marks a significant step…
-
Zai Lab Ltd Reports 46% YOY Revenue Growth in Q3 2024 Driven by Vygart, Zejula, and Nuzyra
•
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its Q3 2024 financial report, showcasing robust growth and providing updates on recent product highlights and corporate developments. Revenue Growth and Product PerformanceDuring Q3, Zai Lab reported product net revenues of USD 101.8 million, a 46% year-on-year (YOY) increase…
-
Legend Biotech’s Q3 Revenue Soars 67% YOY Driven by Carvykti Sales
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced its financial results for the third quarter of 2024, reporting a significant increase in revenue. The company generated USD 160 million in revenue for the three months ended September 30, 2024, marking a 67% year-on-year (YOY) increase. Revenue Breakdown and Key DriversCollaboration…
-
Canhelp Genomics Partners with Mirxes to Expand Tumor Origin Testing in Southeast Asia
•
Canhelp Genomics, a Chinese company specializing in oncology-focused molecular diagnostics, has formed a strategic partnership with Mirxes Singapore. Together, they will utilize their combined technological and operational strengths to offer solid tumor origin identification testing services to medical practitioners and patients in Singapore, Malaysia, Thailand, Indonesia, and the Philippines. Collaboration…
-
Vesalius Therapeutics Partners with GSK for Novel Parkinson’s Disease Treatments
•
US-based Vesalius Therapeutics has entered into a strategic agreement with UK pharmaceutical giant GSK plc (NYSE: GSK, LON: GSK) to discover and develop innovative treatments for Parkinson’s disease (PD) and another undisclosed neurodegenerative condition. The alliance leverages Vesalius’ platform to identify novel intervention points in PD and an additional neurodegenerative…
-
Flare Therapeutics and Roche Enter Strategic Collaboration for Oncology Drug Discovery
•
US-based Flare Therapeutics Inc., a clinical-stage biotech company specializing in cancer therapies through the use of transcription factors, has announced a strategic discovery collaboration agreement with Swiss pharmaceutical giant Roche (SWX: ROG). The partnership will utilize Flare Therapeutics’ expertise in proteomics and mass spectrometry, along with its proprietary library of…
-
Schrödinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates
•
New York-based Schrödinger, Inc. (NASDAQ: SDGR), a leading software provider in accelerating drug discovery, has announced a strategic research collaboration and license agreement with Novartis (NYSE: NVS). This partnership is aimed at advancing multiple development candidates into Novartis’s portfolio for further development. Additionally, the two companies have reached an expanded…
-
CSPC Pharmaceutical Gains NMPA Approval for Clinical Trial of mRNA Vaccine SYS6026
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its therapeutic bivalent mRNA vaccine, SYS6026. This vaccine is indicated for the treatment of precancerous lesions caused by human papillomavirus (HPV) types 16 or 18. Vaccine…
-
NHSA and MoF Announce Medical Insurance Fund Prepayment Initiative to Aid Healthcare Institutions
•
The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MoF) have jointly issued a notification regarding the implementation of a medical insurance fund prepayment initiative. This program is designed to provide financial relief to designated medical institutions by prepaying a portion of the medical insurance fund, thereby easing…
-
InnoCare Pharma Reports 29.8% Revenue Increase in Q3 2024 Financials
•
Beijing-based biotech InnoCare Pharma (HKG: 9969; SHA: 688428) has released its financial report for the third quarter of 2024, ending September 30, 2024, along with operational updates. The company reported revenue of RMB 698 million (USD 96.9 million) for the first three quarters, marking a 29.8% increase over the same…
-
Triton Partners Mulls Acquisition of Germany’s Evotec SE, Shares Soar 22%
•
Private equity firm Triton Partners is reportedly contemplating the acquisition of Germany-based Evotec SE (NASDAQ: EVO), as per information from Reuters. This news catalyzed a 22% surge in Evotec’s shares on Monday, reflecting market anticipation of the potential deal. Triton’s Interest and ShareholdingTriton Partners has been in the process of…
-
GenScript Biotech Expands in Australia with New Sydney Operations and Logistics Center
•
GenScript Biotech Corporation (HKG: 1548), a leading Chinese biotechnology company, has announced the establishment of a new operations site and logistics center in Sydney, Australia. This strategic move highlights GenScript’s commitment to supporting the burgeoning biotechnology sector in Australia. Sydney Facility’s Role in Streamlining OperationsThe new Sydney facility is designed…
-
Leman Biotech Secures Over USD 13.9 Million in Series A Financing for Next-Gen Cancer Immunotherapies
•
China-based Leman Biotech Co., Ltd. has reportedly completed the first closing of its Series A financing round, raising over RMB 100 million (USD 13.9 million). The round was led by Fuho Capital, with additional contributions from Jun Yi Investment and AI-driven drug R&D leader XtalPi (QuantumPharm, HKG: 2228). The funds…
-
Biocytogen’s First-in-Class B7H3/PTK7 Bispecific ADC Option Exercised by IDEAYA Biosciences
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced that its US partner IDEAYA Biosciences Inc. (NASDAQ: IDYA) has exercised its option for an exclusive worldwide license for Biocytogen’s IDE034. This potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) represents a significant step forward in…
-
Gan & Lee’s GZR18 Shows Significant Weight Loss in Phase IIb Study at ObesityWeek 2024
•
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the oral presentation of results from the Phase IIb study for its glucagon-like peptide-1 (GLP-1) receptor agonist, GZR18, at ObesityWeek 2024. The drug is administered once per week and targets the obese or overweight Chinese population. Study Design…
-
J&J’s Nipocalimab Receives FDA Breakthrough Therapy Designation for Sjögren’s Disease
•
US-based pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that it has received Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration (FDA) for its investigational drug nipocalimab. The designation is for the treatment of moderate-to-severe Sjögren’s disease (SjD), a chronic autoantibody disease with a high…
-
Zai Lab and argenx Receive NMPA Approval for Vygart Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
•
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its US partner argenx SE (NASDAQ: ARGX) have announced the receipt of supplementary Biologic License Application (sBLA) approval from the National Medical Products Administration (NMPA) for Vygart Hytrulo (efgartigimod alfa subcutaneous injection; SC). This approval allows Vygart Hytrulo to be…
